Is Pot Stock Tilray Inc. Overvalued?

by Trefis Team
Rate   |   votes   |   Share

Tilray Inc. (NASDAQ: TLRY) became the first marijuana company to have an initial public offering on the U.S. stock exchange. While other marijuana companies are also listed on American exchanges, such as Cronos Group and Canopy Growth Corp., they were first listed on Canadian exchanges. With recreational marijuana use legalized in Canada, effective October 2018, along with medical cannabis usage allowed in a number of international markets, this market is expected to boom. Keeping this in mind, many pot companies are scrambling to expand their capacity, including Tilray. Since its debut on NASDAQ in July at $17 per share, Tilray’s stock has been very volatile, increasing as much as 80% on its second day of listing, consequently having its value cut by over 40%, and then going on another bull run. The shares currently trade at roughly $27, about 57% above its listing price. Given the substantial rise in its price, we feel the stock is currently slightly overvalued.

We currently estimate a price of $25 for Tilray Inc. We have created an interactive dashboard analysis Our Outlook For Tilray Inc. In FY 2018 to estimate Tilray Inc.’s Valuation based on its expected revenues for FY 2018. If you disagree with our forecast, you can make changes to these variables to arrive at your own price estimate for the stock.

We have arrived at a $25 price estimate for Tilray Inc. based on revenue projections of $30.5 million for 2018, a P/S multiple of 70, and a share count of 83 million. The market price stood at $26.67 as of August 13, 2018, implying our price estimate is lower by 3%.

The P/S multiple in this industry has been considerably high, given the tremendous growth expected in the coming years. Investors have been willing to buy the shares of pot stocks at significant premiums, with other companies in the space garnering P/S multiples touching 100. Moreover, with the addition of recreational marijuana use and increasing international opportunities, the revenues for companies like TLRY should grow immensely from FY 2019 onward. The legalization of recreational marijuana may also lure tobacco companies such as Philip Morris International (NYSE:PM), who may look to acquire one of the marijuana producers, which may further push the stock price of these companies higher.

Besides growth in the overall medical cannabis market, there are a number of other factors that should result in a rise in both the revenue drivers – grams sold and average price per gram, as well as growth in the sales of accessories.

1. Capacity Expansion: Tilray intends to use much of the capital raised through its IPO on building out its capacity to meet the significant increase in demand anticipated. Once the planned additional facilities are completed, the company believes that its total production space across all facilities worldwide will total a mammoth 912,000 square feet by the end of 2018. Moreover, the maximum potential development would be 3.8 million square feet, leaving plenty of room to increase production.

2. Expansion Into International Markets: Although cannabis is still heavily regulated, medical use is now authorized at the national or federal level in 28 countries. Moreover, more than 24 of these countries have passed significant reforms to their cannabis use laws to broaden the scope of permitted use since 2015. TLRY’s products have been made available internationally in Argentina, Australia, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. The company is also reported to be the first to legally export medical cannabis from North America to Africa, Australia, Europe, and South America.

3. Partnership With Novartis: Tilray has signed a collaboration agreement with Sandoz Canada, a division of Novartis, to market its non-combustible products. The two companies will together develop new cannabis products, with Sandoz co-branding them for prescription by licensed healthcare professionals. This may help Tilray in producing new products, while helping reduce the R&D costs, as a result of the co-development agreement.

4. Supply Agreements: The company has entered into a definitive agreement to supply Shoppers, the largest pharmacy chain in Canada, with its cannabis products. TLRY has also signed a binding letter of intent to be a preferred supplier of cannabis products to Pharmasave, one of the largest independent pharmacy chains in Canada. The pot company has also negotiated agreements to supply certain provinces and territories with cannabis products. This includes an agreement to supply Quebec’s Société des alcools du Quebec with initially up to 5,000 kilograms of cannabis products per year for three years. TLRY will also provide the Yukon Liquor Corporation with up to 900 kilograms of cannabis products over three years.

5. Cannabis Edibles Market Opportunity: The company expects its High Park Processing Facility to be licensed and operational during the third quarter of 2018. Tilray intends to produce a range of products at this facility once permitted under regulations, including edibles, beverages, capsules, vaporizer oils, tinctures, sprays, topicals, pre-rolls, and dried flower products. While it is currently not legal in Canada, Health Canada did set a one year deadline for forming the regulations. The appeal of the edibles market is expected to increase at a fast pace once legalized, given its growth in the U.S.  For example, in Colorado, the share of edibles and concentrates went up from 11% and 13% at the beginning of 2014 to 15% and 29% by the end of 2017. Furthermore, in California and Oregon, their combined share exceeds 35%.

As a result of the above factors, and consequently a growth in the revenue metrics, we expect the sales to increase to roughly $30.5 million in FY 2018.

 

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs

For CFOs and Finance Teams | Product, R&D, and Marketing Teams

More Trefis Research

Like our charts? Explore example interactive dashboards and create your own.

Rate   |   votes   |   Share

Comments

Name (Required)
Email (Required, but never displayed)
Be the first to comment!